Total Payments
$45,508
2024 Payments
$7,127
Companies
78
Transactions
924
Medicare Patients
13,253
Medicare Billing
$9.2M
Payment Breakdown by Category
Consulting$24,120 (53.0%)
Food & Beverage$17,841 (39.2%)
Other$1,550 (3.4%)
Research$1,270 (2.8%)
Education$650.40 (1.4%)
Travel$77.08 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $24,120 | 13 | 53.0% |
| Food and Beverage | $17,841 | 870 | 39.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,550 | 2 | 3.4% |
| Unspecified | $1,270 | 2 | 2.8% |
| Education | $650.40 | 35 | 1.4% |
| Travel and Lodging | $77.08 | 2 | 0.2% |
Payments by Type
General
$44,238
922 transactions
Research
$1,270
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $16,273 | 68 | $0 (2024) |
| PFIZER INC. | $4,392 | 124 | $0 (2024) |
| Eisai Inc. | $4,210 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,254 | 61 | $0 (2024) |
| ADC Therapeutics America, Inc. | $2,115 | 2 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,951 | 17 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,242 | 97 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,031 | 51 | $0 (2024) |
| Janssen Biotech, Inc. | $955.91 | 65 | $0 (2024) |
| Astellas Pharma US Inc | $715.14 | 36 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,127 | 166 | PFIZER INC. ($3,208) |
| 2023 | $14,740 | 148 | AstraZeneca Pharmaceuticals LP ($7,531) |
| 2022 | $3,825 | 85 | EISAI INC. ($2,020) |
| 2021 | $3,927 | 64 | GlaxoSmithKline, LLC. ($1,674) |
| 2020 | $3,246 | 21 | AstraZeneca Pharmaceuticals LP ($2,838) |
| 2019 | $6,019 | 175 | AstraZeneca Pharmaceuticals LP ($3,318) |
| 2018 | $2,581 | 161 | Novartis Pharmaceuticals Corporation ($319.98) |
| 2017 | $4,043 | 104 | Novartis Pharmaceuticals Corporation ($2,367) |
All Payment Transactions
924 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $15.78 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/26/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: Genetically Defined Disease | ||||||
| 12/23/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: CELLT | ||||||
| 12/19/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $31.34 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $3.25 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $32.71 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $29.95 | General |
| Category: Oncology | ||||||
| 11/25/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.40 | General |
| 11/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $40.10 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $33.08 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.90 | General |
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.52 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), DARZALEX | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: Oncology | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), DARZALEX | Food and Beverage | In-kind items and services | $1.78 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $31.37 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/31/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $27.23 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $35.83 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $26.27 | General |
| Category: Oncology | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 45 | 2,926 | 73,865 | $8.3M | $2.1M |
| 2022 | 56 | 3,413 | 227,703 | $9.7M | $2.3M |
| 2021 | 56 | 3,673 | 114,062 | $9.0M | $2.3M |
| 2020 | 53 | 3,241 | 107,867 | $9.2M | $2.5M |
Total Patients
13,253
Total Services
523,497
Medicare Billing
$9.2M
Procedure Codes
210
All Medicare Procedures & Services
210 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 26,400 | $3.8M | $1.1M | 29.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 88 | 139 | $945,873 | $240,986 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 548 | 1,360 | $484,412 | $149,445 | 30.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 30 | 5,340 | $350,298 | $98,083 | 28.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 63 | 535 | $349,890 | $75,820 | 21.7% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 85 | 137 | $156,537 | $39,139 | 25.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 80 | 108 | $148,236 | $33,707 | 22.7% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 11 | 4,780 | $138,005 | $28,861 | 20.9% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 20 | 4,651 | $215,739 | $26,958 | 12.5% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 14 | 1,500 | $107,157 | $25,243 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 113 | 113 | $67,647 | $21,160 | 31.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 47 | 637 | $92,109 | $19,346 | 21.0% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 78 | 106 | $98,999 | $19,073 | 19.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 177 | 255 | $66,331 | $18,693 | 28.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 15 | 122 | $380,362 | $15,957 | 4.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 25 | 197 | $62,091 | $13,605 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 53 | 75 | $34,319 | $12,272 | 35.8% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 27 | 35 | $86,264 | $11,983 | 13.9% |
| 77049 | Mri scan of both breasts | Office | 2023 | 26 | 33 | $41,272 | $10,806 | 26.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 322 | 1,368 | $43,286 | $10,398 | 24.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 328 | 1,136 | $18,864 | $9,542 | 50.6% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 61 | 77 | $59,745 | $8,131 | 13.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 97 | $21,984 | $7,605 | 34.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 80 | 489 | $40,830 | $6,749 | 16.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 62 | 69 | $24,991 | $6,184 | 24.7% |
About Dr. Min Yan, M.D
Dr. Min Yan, M.D is a Internal Medicine healthcare provider based in Oakland, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/10/2009. The National Provider Identifier (NPI) number assigned to this provider is 1447499710.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Min Yan, M.D has received a total of $45,508 in payments from pharmaceutical and medical device companies, with $7,127 received in 2024. These payments were reported across 924 transactions from 78 companies. The most common payment nature is "Consulting Fee" ($24,120).
As a Medicare-enrolled provider, Yan has provided services to 13,253 Medicare beneficiaries, totaling 523,497 services with total Medicare billing of $9.2M. Data is available for 4 years (2020–2023), covering 210 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Oakland, CA
- Active Since 02/10/2009
- Last Updated 07/31/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1447499710
Products in Payments
- TAGRISSO (Drug) $6,353
- Lenvima (Drug) $4,210
- IMFINZI (Drug) $3,117
- PDR001 (Drug) $2,137
- CALQUENCE (Drug) $2,101
- IBRANCE (Drug) $2,008
- ZEJULA (Drug) $1,839
- LYNPARZA (Drug) $960.18
- KEYTRUDA (Biological) $915.01
- OPDIVO (Biological) $883.43
- IMBRUVICA (Drug) $373.56
- PADCEV (Biological) $357.02
- XTANDI (Drug) $330.85
- JEVTANA (Drug) $304.52
- DARZALEX (Biological) $294.16
- ENHERTU (Biological) $277.32
- KISQALI (Drug) $252.62
- NINLARO (Drug) $248.53
- GILOTRIF (Drug) $248.07
- Cabometyx (Drug) $226.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Oakland
Jeffrey Burack, M.d, M.D
Internal Medicine — Payments: $592,777
Internal Medicine $592,777
Stephanie Christenson, Md, MD
Internal Medicine — Payments: $424,755
Internal Medicine $424,755
Robert Hagar, M.d, M.D
Internal Medicine — Payments: $70,113
Internal Medicine $70,113
Anita Chang, Md, MD
Internal Medicine — Payments: $27,813
Internal Medicine $27,813
Dr. Robert Bober, Md, MD
Internal Medicine — Payments: $26,112
Internal Medicine $26,112
Oluwayemisi Adejumo, M.d, M.D
Internal Medicine — Payments: $23,341
Internal Medicine $23,341